Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Comparative Effectiveness Research Underway At 28 Research Centers
"You hear the pitch in drug ads all the time: "Ask your doctor if this medication is right for you,"" reports MSNBC. However, evidence to show whether a treatment is appropriate for a given patient is often scarce. Matching therapies to patients is further complicated by vast difference in how people respond to medicines. However, a national push for so-called comparative effectiveness research could make that job easier. The economic stimulus package includes $1 billion to support the research.
generic viagra online
Hoyer Objects To Medicare Cost Control Plan
House Majority Leader Steny Hoyer, D-Md., said he disagrees with President Obama"s support of transferring Congress"s price-setting powers over Medicare to the Medicare Payment Advisory Commission (MedPAC), which now acts as an advisory panel, USA Today reports. In a letter to senators Wednesday, Obama floated support for the idea: "Under this approach, MedPAC"s recommendations on cost reductions would be adopted unless opposed by a joint resolution of the Congress."
News of the day
University Of Queensland's Physiotherapist Treats World Champion Cyclist, Australia
Using ultrasound imaging, UQ physiotherapist Dr Julie Hides is helping a world-champion cyclist ride her bike pain free.
Health Insurance

Health Canada Update About Safety Of Lantus (Insulin Glargine)

Health Canada is informing Canadians of an ongoing safety review of the potential association between the diabetes drug Lantus (insulin glargine) and an increased risk of developing cancer. A similar review was recently announced by the U.S. Food and Drug Administration and the European Medicines Agency in light of four recently published studies that looked at the use of Lantus and the development of various types of cancer in patients with diabetes. Three of the four studies suggested a very slightly increased risk of cancer associated with use of Lantus, while the fourth study found no link between the drug and the development of cancer. In all studies, the number of patients who developed cancer was small. The four studies were published in Diabetologia. Lantus is a long-acting synthetic insulin similar to human insulin that is used to control blood sugar in people with type 1 and type 2 diabetes. It has been marketed in Canada since February 2005 by the company Sanofi-Aventis. At this time, Health Canada recommends that patients should not stop taking their insulin therapy without first consulting their physician, as uncontrolled blood sugar can have both immediate and long term serious health consequences. Patients should contact their health care professional if they have any concerns about the medicines they are taking. Health Canada has not concluded that there is a relationship between Lantus and the development of cancer. The Department is currently assessing available safety data, including the studies, to better understand the risk, if any. Health Canada will inform Canadians and health care professionals of new safety information as it emerges, as appropriate. You can report any adverse reactions associated with the use of Lantus to the Canada Vigilance Program by one of the following three ways: - Report online at the MedEffect™ Canada section of the Health Canada Web site - Call toll-free at 1-866-234-2345 - Complete a Canada Vigilance Reporting Form and either: Fax toll-free to 1-866-678-6789 Mail to: Canada Vigilance Program Health Canada AL 0701C Ottawa, ON K1A 0K9 Health Canada


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009